Publications by authors named "E Cognat"
J Am Med Dir Assoc
November 2024
Article Synopsis
- Dementia, particularly with severe behavioral and psychological symptoms (BPSD), greatly affects quality of life and is a main cause of death in older adults; this study looked at factors predicting mortality in these patients.
- Over 4 years, 32.5% of 508 participants with severe BPSD died, with non-survivors generally being older, more likely male, and showing greater symptom severity and lower cognitive and functional capabilities at the start.
- Key mortality predictors identified were male sex, older age at diagnosis, higher BPSD severity scores, lower cognitive function, worse daily living capabilities, and lower quality of life, while the use of antidepressants was linked to a reduced mortality risk.
Article Synopsis
- Recent advancements in Alzheimer's treatment now require verification of amyloid-β pathology using PET scans or cerebrospinal fluid, but blood tests could simplify this process.*
-
- A study involving nearly 7,000 individuals identified that the plasma biomarker p-tau217 can reliably indicate amyloid-β pathology, especially in patients with probable Alzheimer’s dementia.*
-
- The findings suggest that combining p-tau217 results with clinical assessments may allow for accurate diagnoses without the need for more invasive PET or CSF tests.*
Alzheimers Res Ther
October 2024
Article Synopsis
- The study investigates the relationship between plasma neurofilament light (NfL) protein levels and cognitive impairment across various patient groups, including Alzheimer’s disease and other dementias.
- The research was conducted on 320 patients, measuring NfL levels and assessing cognitive performance, with significant associations found between higher NfL levels and lower cognition, particularly in memory and executive functions.
- Despite noteworthy findings, the clinical application of plasma NfL in daily practice for unselected cognitive impairment patients remains largely unaddressed.
Alzheimers Res Ther
July 2024
Article Synopsis
- Research indicates that plasma biomarkers related to amyloid, tau, neurodegeneration, and neuroinflammation could be useful in diagnosing dementia, but their effectiveness for diagnosing dementia with Lewy bodies (DLB) specifically remains unclear.
- A study involving patients with DLB, Alzheimer's disease (AD), and neurological controls measured various plasma biomarkers and found that DLB patients had altered biomarker levels compared to controls and AD patients.
- Plasma p-tau181 was the most effective biomarker for distinguishing DLB from AD and controls, suggesting it plays a key role in identifying amyloid-related issues in DLB, although the overall diagnostic performance of these biomarkers was moderate.
J Alzheimers Dis
May 2024
Article Synopsis
- - Psychosis, marked by delusions and hallucinations, is common in Alzheimer's and other neurodegenerative dementias, leading to challenges in diagnosis and treatment.
- - A systematic review of 98 studies reveals high prevalence rates of psychotic symptoms across different dementias, with notable patterns such as misidentification delusions in dementia with Lewy bodies and paranoid ideas in Alzheimer's.
- - The findings highlight significant variations in psychotic symptoms among different neurodegenerative diseases, emphasizing the need for more research on early-stage psychosis to improve diagnosis and management.
